Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Capital Expenditures (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Capital Expenditures readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 21.99% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.5 million, a 16.6% increase, with the full-year FY2025 number at $13.5 million, up 16.6% from a year prior.
  • Capital Expenditures hit $2.4 million in Q4 2025 for Treace Medical Concepts, down from $2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.9 million in Q3 2022 to a low of $196000.0 in Q1 2021.
  • Median Capital Expenditures over the past 5 years was $2.6 million (2025), compared with a mean of $2.7 million.
  • The widest YoY moves for Capital Expenditures: up 1518.97% in 2021, down 70.92% in 2021.
  • Treace Medical Concepts' Capital Expenditures stood at $900000.0 in 2021, then surged by 159.11% to $2.3 million in 2022, then dropped by 3.6% to $2.2 million in 2023, then skyrocketed by 36.74% to $3.1 million in 2024, then decreased by 21.99% to $2.4 million in 2025.
  • The last three reported values for Capital Expenditures were $2.4 million (Q4 2025), $2.8 million (Q3 2025), and $4.8 million (Q2 2025) per Business Quant data.